Kamada Pharmaceuticals - Company Profile

Powered by

All the data and insights you need on Kamada Pharmaceuticals in one report.

  • Save hours of research time and resources with
    our up-to-date Kamada Pharmaceuticals Strategy Report

  • Understand Kamada Pharmaceuticals position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Kamada Pharmaceuticals: Premium Databases

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Kamada Pharmaceuticals Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

A sample of Kamada Pharmaceuticals Regulatory Milestones data

Drug Name Generic Name Brand Name Company Name Expiry Geography Constraining Patent Number Constraining Patent Expiry Drug Expiry (Estimated) Highest Development Stage
Showing 3 of 5 results.
Deserunt mollit sunt Lorem Lorem Lorem Pfizer Inc Lorem WXYZ Lorem Pending Lorem
Antibody for Coronavirus Disease 2019 (COVID-19) - - Kamada Pharmaceuticals United States US20200157242 - Pending Preclinical
Antibody for Zika Virus Infections - - Kamada Pharmaceuticals United States US10689435 Feb-2037 - -
Antibody for Zika Virus Infections - - Kamada Pharmaceuticals United States US10689435 Feb-2037 - -

A sample of Kamada Pharmaceuticals Review Designation data

Drug Name Generic Name Company Name Indication Geography Designation Type Designation Status Designation Date
Showing 3 of 5 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore Lorem Pfizer Inc Lorem Lorem Lorem Lorem 31 Jul 2017
alpha-1 proteinase inhibitor (human) second generation alpha-1 proteinase inhibitor (human) Kamada Pharmaceuticals Bronchiectasis United States Orphan Drug Designation Designated 03 Apr 2008
alpha-1 proteinase inhibitor (human) second generation alpha-1 proteinase inhibitor (human) Kamada Pharmaceuticals Alpha-1 Antitrypsin Deficiency (A1AD) United States Orphan Drug Designation Designated 24 Dec 2004
alpha-1 proteinase inhibitor (human) second generation alpha-1 proteinase inhibitor (human) Kamada Pharmaceuticals Alpha-1 Antitrypsin Deficiency (A1AD) United States Orphan Drug Designation Designated 24 Dec 2004
Regulatory Milestones

Feature

Regulatory Milestones provides an interactive, comprehensive, and analytical view of Drug and Constraining Patent Expiry and Exclusivity for Marketed and Pipeline (till preclinical development stage) pharmaceutical drugs in the United States (US), Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.

Benefit

Regulatory Milestones provides patent information for all novel Marketed and Pipeline pharmaceutical drugs available in the US, Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.

The Drug Expiry filters include Expiry Geography and Expiry Date as well as US-specific information.

The Drug Expiry date is based on the Constraining Patent Expiry, Patent Term Extension or Supplementary Protection Certificate (depending on the regulator), Exclusivity analysis and specific information on Review Designations granted by regulators.

US-specific information includes Exclusivity Type and Paragraph IV Certification filing under the Hatch Waxman Act (Paragraph IV).

Value

Regulatory Milestones is easily accessible and features a user-friendly platform. The tool includes attributes relating to Drug Expiry and Constraining Patents as well as attributes from Drugs and Companies .

Clients can utilize Regulatory Milestones to save time and effort through accumulated expiry information from various sources and registries in a standardized comparable format.

Premium databases is part of our industry range of products

Gain a 360-degree view of Kamada Pharmaceuticals and make more informed decisions for your business
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer